Pharmacodynamic basis of the use of vasodilators in the treatment of heart failure.
D002302:Cardiac Output; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D009200:Myocardial Contraction; D005996:Nitroglycerin / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D004232:Diuretics; D014665:Vasodilator Agents; D006830:Hydralazine; D005996:Nitroglycerin; D011224:Prazosin; D010646:Phentolamine